Iris Burkholder

2.4k total citations
62 papers, 1.4k citations indexed

About

Iris Burkholder is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Iris Burkholder has authored 62 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 16 papers in Surgery. Recurrent topics in Iris Burkholder's work include Colorectal Cancer Treatments and Studies (6 papers), Advanced MRI Techniques and Applications (6 papers) and MRI in cancer diagnosis (5 papers). Iris Burkholder is often cited by papers focused on Colorectal Cancer Treatments and Studies (6 papers), Advanced MRI Techniques and Applications (6 papers) and MRI in cancer diagnosis (5 papers). Iris Burkholder collaborates with scholars based in Germany, Switzerland and France. Iris Burkholder's co-authors include Lutz Edler, Annette Kopp‐Schneider, Klaus Schneider, Markus Schwarz, Agnieszka Kinsner‐Ovaskainen, Thomas Härtung, Sebastian Hoffmann, Hans‐Ulrich Kauczor, Marc‐André Weber and Eckart Laack and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Scientific Reports.

In The Last Decade

Iris Burkholder

58 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Iris Burkholder Germany 19 363 356 343 245 215 62 1.4k
Hiroyuki Shimada Japan 24 434 1.2× 192 0.5× 484 1.4× 179 0.7× 126 0.6× 100 1.9k
Michael T. Falta United States 25 224 0.6× 306 0.9× 462 1.3× 109 0.4× 149 0.7× 43 1.7k
Shruti Agrawal United Kingdom 19 829 2.3× 537 1.5× 253 0.7× 157 0.6× 146 0.7× 73 2.0k
Yuan Tang China 23 636 1.8× 415 1.2× 429 1.3× 345 1.4× 94 0.4× 209 1.8k
Giovanni Rossi Italy 26 790 2.2× 1.0k 2.9× 442 1.3× 329 1.3× 225 1.0× 114 2.3k
William W. West United States 23 679 1.9× 804 2.3× 370 1.1× 217 0.9× 115 0.5× 58 2.1k
Xin Yang China 24 407 1.1× 424 1.2× 645 1.9× 216 0.9× 279 1.3× 141 1.8k
Jan‐Show Chu Taiwan 25 503 1.4× 226 0.6× 991 2.9× 287 1.2× 94 0.4× 74 2.0k
Jian Hu China 27 588 1.6× 1.1k 3.0× 649 1.9× 543 2.2× 307 1.4× 201 2.4k
Claire Goulvestre France 21 201 0.6× 343 1.0× 523 1.5× 104 0.4× 157 0.7× 52 1.9k

Countries citing papers authored by Iris Burkholder

Since Specialization
Citations

This map shows the geographic impact of Iris Burkholder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Iris Burkholder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Iris Burkholder more than expected).

Fields of papers citing papers by Iris Burkholder

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Iris Burkholder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Iris Burkholder. The network helps show where Iris Burkholder may publish in the future.

Co-authorship network of co-authors of Iris Burkholder

This figure shows the co-authorship network connecting the top 25 collaborators of Iris Burkholder. A scholar is included among the top collaborators of Iris Burkholder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Iris Burkholder. Iris Burkholder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bergmann, Lars, Marit Ahrens, M. Gross Goupil, et al.. (2024). LBA75 Prospective randomised phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer: Results of the SUNNIFORECAST trial. Annals of Oncology. 35. S1263–S1263. 14 indexed citations
2.
3.
Zeifang, Felix, et al.. (2023). 3-Tesla T2 Mapping Magnetic Resonance Imaging for Evaluation of SLAP Lesions in Patients with Shoulder Pain: An Arthroscopy-Controlled Study. Journal of Clinical Medicine. 12(9). 3109–3109. 2 indexed citations
4.
5.
Merx, Kirsten, et al.. (2023). Effects of a Sound Intervention on Physical and Emotional Well-Being in Patients with Cancer: A Prospective Randomized Trial. Oncology Research and Treatment. 46(1-2). 1–10. 2 indexed citations
6.
Braun, Alexander, Marc‐An dré Weber, Marcus Schiltenwolf, et al.. (2019). Impact of MRI, CT, and Clinical Characteristics on Microbial Pathogen Detection Using CT-Guided Biopsy for Suspected Spondylodiscitis. Journal of Clinical Medicine. 9(1). 32–32. 10 indexed citations
7.
Zeifang, Felix, Michael W. Maier, Iris Burkholder, et al.. (2019). Diagnostic performance of 3D-multi-Echo-data-image-combination (MEDIC) for evaluating SLAP lesions of the shoulder. BMC Musculoskeletal Disorders. 20(1). 598–598. 5 indexed citations
8.
9.
Hofheinz, Ralf‐Dieter, Ulrich Ronellenfitsch, Stefan Kubicka, et al.. (2016). Treatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized Trials. Gastroenterology Research and Practice. 2016. 1–9. 9 indexed citations
10.
Rickert, Markus, Tobias Gotterbarm, Wolfram Stiller, et al.. (2015). Pelvic X-ray examinations in follow-up of hip arthroplasty or femoral osteosynthesis – Dose reduction and quality criteria. European Journal of Radiology. 84(5). 915–920. 9 indexed citations
11.
Rehnitz, Christoph, N. Streich, Iris Burkholder, et al.. (2014). Comparison of biochemical cartilage imaging techniques at 3 T MRI. Osteoarthritis and Cartilage. 22(10). 1732–1742. 53 indexed citations
12.
Bergmann, Lothar, Luise Maute, Gerhard Heil, et al.. (2014). A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer. European Journal of Cancer. 51(1). 27–36. 51 indexed citations
13.
14.
Andritzky, Birte, Gunter Schuch, Iris Burkholder, et al.. (2010). Elevated pretreatment serum concentration of YKL‐40—An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer. Cancer. 116(17). 4114–4121. 56 indexed citations
15.
Habermann, Christian R., Gunter Schuch, Birte Andritzky, et al.. (2008). A Pilot Study of Docetaxel and Trofosfamide as Second-Line ‘Metronomic’ Chemotherapy in the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC). Onkologie. 31(4). 185–189. 22 indexed citations
16.
Sangrajrang, Suleeporn, Peter Schmezer, Iris Burkholder, et al.. (2007). TheXRCC3Thr241Met polymorphism and breast cancer risk: a case–control study in a Thai population. Biomarkers. 12(5). 523–532. 27 indexed citations
17.
Burkholder, Iris, Birte Andritzky, Christian Kügler, et al.. (2007). Lectin histochemistry of metastatic adenocarcinomas of the lung. Lung Cancer. 56(3). 391–397. 16 indexed citations
18.
Laack, Eckart, Iris Burkholder, Birte Andritzky, et al.. (2005). Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC). Lung Cancer. 50(1). 51–58. 38 indexed citations
19.
Gorn, Michael H., Iris Burkholder, Lutz Edler, et al.. (2005). Serum levels of Magic Roundabout protein in patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer. 49(1). 71–76. 13 indexed citations
20.
Burkholder, Iris & Annette Kopp‐Schneider. (2002). Incorporating phenotype-dependent growth rates into the color-shift model for preneoplastic hepatocellular lesions. Mathematical Biosciences. 179(2). 145–160. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hiroyuki Shimada Breakdown of academic impact, for papers by Michael T. Falta Breakdown of academic impact, for papers by Shruti Agrawal Breakdown of academic impact, for papers by Yuan Tang Breakdown of academic impact, for papers by Giovanni Rossi Breakdown of academic impact, for papers by William W. West Breakdown of academic impact, for papers by Xin Yang Breakdown of academic impact, for papers by Jan‐Show Chu Breakdown of academic impact, for papers by Jian Hu Breakdown of academic impact, for papers by Claire Goulvestre
Rankless by CCL
2026